1. Efficacy and quality of life after 6-9 years of deep brain stimulation for depression.
- Author
-
Bergfeld IO, Ooms P, Lok A, de Rue L, Vissers P, de Knijff D, Horst F, Beute G, van den Munckhof P, Schuurman PR, and Denys D
- Subjects
- Adult, Depression therapy, Humans, Quality of Life, Treatment Outcome, Deep Brain Stimulation adverse effects, Depressive Disorder, Treatment-Resistant therapy
- Abstract
Background: Given the invasiveness of deep brain stimulation (DBS), the effect should prove to be stable over the long-term and translate into an improvement of quality of life (QOL)., Objective: To study the effectiveness and QOL up to nine years after the DBS surgery., Methods: We treated 25 adult patients with major depression with DBS of the ventral anterior limb of the internal capsule (vALIC). We followed them up naturalistically for 6-9 years after surgery (mean: 7.7 [SD:1.5] years), including a randomized crossover phase after the first year comparing sham with active DBS. Symptom severity was quantified using the Hamilton Depression Scale with response defined as a ≥50% decrease of the score compared to baseline. Quality of life was measured using the WHOQOL-BREF, assessing 5 domains (general, physical, psychological, social, environmental)., Results: Intention-to-treat response rates remained mostly stable from Year 3 to last follow-up (Year 3, 5 and 6: 40%; Year 4: 36%; Last observation: 44%). General, physical, psychological (all P < 0.001) and the environmental (P = 0.02) domain scores increased during DBS optimization and remained stable over the long term. No statistically significant changes were detected on the social domain. Patients scored significantly higher during active than sham DBS on the psychological, social and environmental domains, and trended towards a higher score on the general and physical domains., Conclusion: This study shows continued efficacy of vALIC DBS in depression, which translates into an improvement of QOL providing further support for DBS as a durable treatment for TRD., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This investigator-initiated study was funded by Medtronic Inc (25 DBS systems, in kind) and a grant from ZonMw (nr. 171201008). The funders had no role in the design, execution, and analysis of the study, nor in writing of the manuscript or the decision to publish. Isidoor Bergfeld, Anja Lok, Dirk de Knijff, Ferdinand Horst, Pepijn van den Munckhof, P. Richard Schuurman, and Damiaan Denys currently execute an investigator-initiated clinical trial on deep brain stimulation for depression, which is funded by Boston Scientific (24 DBS systems in kind) and a grant of ZonMw (nr. 636310016). P. Richard Schuurman acts as an independent advisor for Medtronic and Boston Scientific. All other authors do not declare any conflicts of interest., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF